Isomorphic Labs Raises $2.1B in Series B Led by Thrive Capital

According to Bloomberg, Isomorphic Labs, a drug discovery company spun out of Google DeepMind in 2021, raised $2.1 billion in a Series B funding round led by Thrive Capital on May 12. Alphabet, MGX, Temasek, CapitalG, GV, and the UK Sovereign AI Fund also participated in the round.

The company will use the funding to expand its AI drug design engine IsoDDE and hire across AI, engineering, drug design, and clinical teams. Isomorphic Labs has partnerships with pharmaceutical companies including Eli Lilly and Novartis.